Oncology

Map of China
#Artificial intelligence (AI) #China #Metabolic diseases #Oncology

Is China the next global biopharma powerhouse?

Regulatory reform and investment in innovation have supercharged China’s biopharma sector, but will ongoing trade wars with the US pose a risk to growth? By Diana Turner. China’s role in the global biopharma sector has grown significantly in recent years. It is the world's largest supplier of active pharmaceutical ingredients (APIs) and in… Read More

#Exclusive Content #Market Reports

#Mosaic Therapeutics #Oncology

Thomas Fuchs appointed CEO of Mosaic Therapeutics

Oncology therapeutics company Mosaic Therapeutics has appointed Thomas Fuchs as its CEO.  Fuchs has over 25 years of experience in leadership positions across early drug development, commercialisation and life cycle management, serving in senior oncology biopharma leadership roles in both oncology-focused biotech and big pharma. He was… Read More

#News

Cancer cells
#Chemotherapy #Drug discovery #Neuropathy #Oncology

Reducing the side-effects of chemotherapy  

DDW speaks to Yasuo Nakamura, Senior Executive Officer at Pharmaceuticals R&D, Asahi Kasei Pharma Corporation about the challenges of treating chemotherapy-induced peripheral neuropathy (CIPN) and the company’s current pipeline targeting the condition.   DDW: What makes chemotherapy-induced peripheral neuropathy (CIPN) such a persistent challenge in colorectal cancer care, and why has… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Molecular glue degrader #Oncology

Are DACs the new ADCs?

DDW Editor Reece Armstrong speaks to SJ Lee, Founder and CEO of Orum Therapeutics, about the potential of degrader-antibody conjugates (DACs) in treating previously “undruggable” diseases.   RA: How do DACs work? SL: Degrader-antibody conjugates (DACs) combine two proven concepts—antibody precision and catalytic protein degradation—into a single, modular medicine. First, a… Read More

#Exclusive Content

#Collaboration #Immunotherapy #Oncology

French partnership aims to advance immunotherapies

A trio of French organisations across pharma, government and academia have partnered with the aim of accelerating immunotherapy for oncology, inflammation, and autoimmunity research. OSE Immunotherapeutics, Inserm Transfert and Nantes University have signed a strategic partnership which will combine academic research with industrial expertise to bring more immunotherapies… Read More

#Cancer Research #News

#Cancer research #Oncology #The Francis Crick Institute #Vividion Therapeutics

Research identifies compounds preventing cancer gene mutation

New research has identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key pathway for tumour growth.   Researchers from the Francis Crick Institute and Vividion Therapeutics identified compounds that can block the RAS gene from mutating without preventing the… Read More

#News

Protein degradation
#Frontier Medicines #Oncology #Precision medicine #Protein degradation

Study identifies new E3 ligase for targeted protein degradation

A new study in Structure, a Cell Press journal demonstrates that DCAF2 can be harnessed as a novel E3 ligase for targeted protein degradation (TPD).   The authors say DCAF2 presents an exciting opportunity to deliver tumour-targeted protein degraders given its frequent overexpression in various types… Read More

#Cancer Research #News

GBP pound sterling funding
#Biotechnology #Financing #Fundraising #Oncology

Trogenix secures £70m to advance oncology pipeline

Biotech company Trogenix has secured £70 million ($95 million) in funding to help advance its pipeline of cancer therapies.   The Series A funding was led by IQ Capital and invested in by 4BIO Capital, alongside new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital. The round also included… Read More

#Business & Investment #News

#Long Covid #Oncology #Pancreatic cancer

DDW Highlights: 7 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news. This week’s news is led by the agreement by Genmab to acquire Merus, an announcement… Read More

#Podcasts

#3D modelling #Career #Interview #Meet the Researcher #Oncology #Pancreatic cancer

Meet the researcher: Catherine Whittington, Associate Professor

DDW’s Diana Turner speaks to Catherine Whittington, Associate Professor in the Department of Biomedical Engineering at WPI about her current work and the research that drives her.   DT: Can you tell us what you do and what you’re working on at the moment? CW: I teach classes in the biomedical engineering (BME)… Read More

#Exclusive Content

Bispecific antibodies
#Bispecific Antibodies #Genmab #Head and neck cancer #Mergers and acquisitions #Oncology

Genmab to acquire Merus for approximately $8 billion

Genmab has agreed to acquire Merus, a clinical-stage biotechnology company with a late-stage breakthrough therapy asset called petosemtamab, which is in Phase III development.  Genmab will pay $97.00 per share in an all-cash transaction representing a transaction value of approximately $8 billion.   The proposed acquisition of Merus is expected to… Read More

#Business & Investment #News

microRNA
#Collaboration #Lipid based nanoparticle (LNP) #Oncology #Partnership #Quantoom Biosciences #RNA

Quantoom and MSK unite on personalised cancer therapies

Memorial Sloan Kettering Cancer Center (MSK) and Quantoom Biosciences have executed a non-exclusive research license and supply agreement to support the development of personalised cancer therapies using Quantoom’s lipid nanoparticle (LNP) formulation technology, Ncapsulate QCX-002.  Under the agreement, MSK will use Ncapsulate QCX-002, an LNP delivery chemistry… Read More

#Cancer Research #News

Breast cancer
#Breast cancer #Eli Lilly #FDA #Gene mutation #Oncology

FDA approves Inluriyo in ER+, HER2-, ESR1-mutated breast cancer

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Inluriyo (imlunestrant, 200mg tablets), an oral oestrogen receptor antagonist.  It is approved for the treatment of adults with oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after… Read More

#News #Regulatory #Trending News

#Brain cancer #European Commission #Oncology #Servier Pharmaceuticals

Servier’s targeted brain tumour therapy approved in EU

The European Commission has approved pharmaceutical company Servier’s Voranigo therapy for patients with a specific type of brain tumour.   Voranigo has now been approved for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation in adult and… Read More

#News #Regulatory

#Cancer research #Immunoassay #Oncology #PROTAC #Protein degradation #Webinar

Last chance to register: PROTAC-Mediated CDK2 degradation in oncology

Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More

Webinar date:
Supported by Revvity
#News

#Biomarkers #Oncology #Whitepaper

Learn about protein biomarkers shaping cancer outcomes in the tumour microenvironment

The tumour microenvironment (TME) is no longer considered a passive backdrop to cancer. It is a dynamic ecosystem that plays a central role in tumour growth, immune suppression, metastasis and treatment resistance. Whitepaper highlights: Understand how the TME drives cancer progression, immune evasion and therapeutic resistance Explore emerging strategies that… Read More

#Resources